A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis
- 1 November 2004
- journal article
- Published by Elsevier in Antiviral Research
- Vol. 64 (2) , 103-111
- https://doi.org/10.1016/s0166-3542(04)00131-7
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: